Genelux is committed to pursuing clinical trials in cancers with significant unmet need, and to pursue an aggressive strategy to ensure our therapies are on the most expeditious path to market for the benefit of cancer patients.
Genelux conducted its First-In-Man Phase I clinical trial of GL-ONC1 in Various Solid Tumor Cancers, establishing delivery of virus and replication in tumors, and finding promising early signs of efficacy across several tumor types. Please click here for details.

In addition, GL-ONC1 is evaluated in additional Phase I/II clinical trials in a variety of cancers and Phase II trials are in the planning stages.

  • Ongoing Clinical Trials
    • Phase Ib/2a Study: GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer
      • Status: Recruiting
      • For link to Clinical Trials.gov listing click here.
      • Principal Clinical Investigator: Robert W. Holloway, MD, FACOG, FACS (Florida Hospital Cancer Institute)
      • Contact: Susan Coakley; 407-303 2090; susan.coakley@flhosp.org
    • Phase Ib Study: Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection
      • Status: Recruiting
      • For link to Clinical Trials.gov listing click here.
      • Principal Clinical Investigator: Kaitlyn Kelly, MD (UC San Diego Moores Cancer Center)
      • Contact: Julie Lewis, CRC, LVN; 858822-4907; jml111@ucsd.edu
  • Future Clinical Trials (Planned)
    • Phase 2 Study: GL-ONC1 (intraperitoneal) in Ovarian Cancer
      • Status: Planning and Submission
    • Phase 2 Study: GL-ONC1 intravenous administration
      • Status: Planning